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Abstract 
Hepatocellular carcinomas (HCCs) are known to be highly heterogenous. Within the extensive histopathological 
and molecular heterogeneity of HCC, tumors with mutations in CTNNB1, encoding -catenin (CTNNB1-mutated 
HCC), constitute a very homogeneous group. We previously characterized a distinctive metabolic and histological 
phenotype for CTNNB1-mutated HCC. They were found to be well-differentiated, almost never steatotic, and often 
cholestatic, with a microtrabecular or acinar growth pattern. Here, we investigated whether LKB1, which controls 
energy metabolism, cell polarity, and cell growth, mediates the specific phenotype of CTNNB1-mutated HCC. 
The LKB1 protein was overexpressed in CTNNB1-mutated HCC and oncogenic activation of  -catenin in human 
HCC cells induced the post-transcriptional accumulation of the LKB1 protein encoded by the LKB1 (STK11) gene. 
Hierarchical clustering, based on the expression of a murine hepatic liver Lkb1 (Stk11) signature in a human public 
dataset, identified a HCC cluster, composed of almost all the CTNNB1-mutated HCC, that expresses a hepatic 
liver LKB1 program. This was confirmed by RT-qPCR of an independent cohort of CTNNB1-mutated HCC and 
the suppression of the LKB1-related profile upon  -catenin silencing of CTNNB1-mutated human hepatoma cell 
lines. Previous studies described an epistatic relationship between LKB1 and CTNNB1 in which LKB1 acts upstream 
of CTNNB1. Thus, we also analyzed the consequences of Lkb1 deletion on the zonation of hepatic metabolism, 
known to be the hallmark of  -catenin signaling in the liver. Lkb1 was required for the establishment of metabolic 
zonation in the mouse liver by positively modulating  -catenin signaling. We identified positive reciprocal cross 
talk between the canonical Wnt pathway and LKB1, both in normal liver physiology and during tumorigenesis that 
likely participates in the amplification of the  -catenin signaling by LKB1 and the distinctive phenotype of the 
CTNNB1-mutated HCC. 
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Introduction 
 
Hepatocellular carcinoma  (HCC)  is  the  fifth  cause 
of cancer-related death worldwide (GLOBOCAN 2012 
v1.0 database, International  Agency  for  Research 
on Cancer, Lyon, France, 2013. Available from: http:// 
globocan.iarc.fr, accessed on 4 June 2018). It is a 
highly heterogeneous disease, with multiple risk factors 
and a large spectrum of histopathological features. 
Large-scale genomic and transcriptomic studies have 
classified HCC according to various molecular sub- 
classes, often associated with clinical and phenotypic 
traits [1 – 3]. Within HCC, tumors with activating 
mutations of the gene encoding β-catenin (CTNNB1) 
(18 – 40% of cases) constitute a very homogeneous 
subgroup [4]. Indeed, we and others have shown that 
CTNNB1-mutated HCCs are well-differentiated, often 
cholestatic, chromosomally stable, and associated with 
a better prognosis than other HCCs [3,4]. Furthermore, 
CTNNB1-mutated HCCs are almost never steatotic and 
usually display microtrabecular and/or acinar growth 
patterns. Tumor cells in pseudoglandular or acinar struc- 
tures show a columnar apicobasal polarity (simple-type 
polarity)  that  differs  from  hepatic  hepatocyte-type 
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polarity [4], which is required for the efficient removal 
of excreted bile [5]. CTNNB1-mutated HCC is also 
classified in the nonproliferative molecular subgroup of 
tumors. In contrast, non-CTNNB1-mutated HCCs dis- 
play heterogeneous histopathological phenotypes, usu- 
ally with a macrotrabecular growth pattern and poorer 
differentiation; steatosis is observed in approximately 
30% of cases, and cholestasis is infrequent [1 – 3]. 
Aside from its oncogenic function in HCC when aber- 
rantly activated, the Wnt/β-catenin canonical pathway 
also plays a critical role in liver physiology as it is 
the master regulator of the establishment of hepatic 
metabolic zonation [6]. 
We previously sought candidate genes that could 
explain the distinctive phenotype of CTNNB1-mutated 
HCCs and identified liver kinase B1 (LKB1), encoded 
by STK11. STK11 encodes a serine/threonine kinase 
that functions as a tumor-suppressor gene. Germline 
mutations of STK11 are associated with Peutz – Jeghers 
syndrome (PJS), an autosomal-dominant disorder that 
is linked to an increased risk of cancer [7,8]. However, 
somatic STK11 mutations are not commonly found in 
sporadic cancers, except lung cancer [9]. The active 
form of LKB1 is found in a heterotrimeric complex 
with STRAD and MO25, which regulate its stability, 
kinase activity, and subcellular localization [10]. LKB1 
has been called a ‘master kinase’ due to its ability to 
phosphorylate at least 14 downstream proteins; the 
AMP-activated protein kinases (AMPK); and 12 pro- 
teins related to AMPK, called ARK for AMP-related 
kinase (ARK) [11]. LKB1 regulates multiple biological 
pathways, including those involved in cell polarity, cell 
metabolism, and cell growth and proliferation [7,8]. 
Strikingly, LKB1  is  a  cell-autonomous  determinant 
of the apical polarity of epithelial cells and can, for 
example, polarize single, isolated  intestinal  epithe- 
lial cells [12]. It negatively controls cell proliferation 
via the AMPK/mTOR, TP53, and YAP cell growth 
signaling pathways [7,8]. Finally, LKB1 coordinates 
the metabolic response to energetic stress, activating 
catabolic processes, such as fatty acid oxidation, and 
inhibiting anabolic pathways, such as lipid synthesis 
[7]. Therefore, the morphologically specific signature of 
CTNNB1-mutated HCCs, namely, low proliferation, the 
lack of steatosis, and the acquisition of a simple type of 
polarity, may be consistent with the activation of LKB1 
in such tumors. This would confer a counterintuitive 
oncogenic function to STK11, which is usually con- 
sidered to be a tumor-suppressor gene. However, this 
oncogenic function of LKB1 has already been observed 
in other settings [13,14]. In addition, numerous studies 
described molecular cross talk between LKB1 and the 
Wnt/β-catenin signaling pathway [15 – 22]. 
Here, we  showed  that  LKB1  is  overexpressed 
in CTNNB1-mutated HCC relative to nonmutated 
HCC and that aberrant activation of β-catenin sig- 
naling induces post-transcriptional accumulation of 
LKB1. Using  an  Lkb1  transcriptomic  signature  that 
we recently established using a liver-specific deletion 
of Lkb1 in embryonic liver [23], we confirmed that 
CTNNB1-mutated HCC express an LKB1 program. In 
addition, we found that LKB1 is required for specific 
physiological functions of β-catenin in the liver and 
exerts a physiological role as a positive modulator of 
β-catenin-dependent metabolic zonation. 
 
 
Methods 
 
Tumor specimens 
We selected 48 samples from the human HCC cohort 
of patients treated for liver cancer in Cochin Hospi- 
tal (Paris,  France),  previously  described  by  Audard 
et al [4], for which we  had both frozen tumor and 
nontumor liver samples. Half of the tumors were 
CTNNB1-mutated, and half were not. All tumor sam- 
ples were frozen after surgery in accordance with French 
laws and ethical guidelines. The frozen samples were 
used for western blotting analyses. We also selected a 
validation set of human HCCs to confirm the expression 
of the hepatic Lkb1 signature in CTNNB1-mutated 
HCC for which the RNA was already available [4]. 
The validation set was composed of samples of 18 
CTNNB1-mutated HCCs and 22 non-CTNNB1-mutated 
HCCs, together with six human normal liver samples. 
The mutational status of the CTNNB1 gene in these 
samples has been described previously [4]. 
 
Animals 
Mice with a specific deletion of Lkb1 in embryonic 
liver, Lkb1lox,lox;Alfp-Cre mice called LKB1KOLivemb, 
have already been described [23]. All animal pro- 
cedures were carried out according to French legal 
regulations and approved by  an  ethical  commit- 
tee (CEEA34.CP.077.12). All mice were kept in 
well-controlled animal housing facilities with free 
access to tap water and food pellets. 
 
Cell culture and transfection assay 
HuH7, HepG2, and HuH6 cells were grown in Dubel- 
cco’s modified Eagle’s medium (DMEM; Gibco, Life 
Technologies, Carlsbad, CA, USA) with 4.5 g/l glucose, 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS)  and  100 U/ml  penicillin/streptomycin 
at 37 ∘C in 5% CO2. 
For siRNA transfections, cells were seeded in six-well 
plates (0.3 × 106 cells per well) and reverse-transfected 
with 100 pmol siRNA in the presence of Lipofectamine 
RNAimax Reagent (Life Technologies) according to 
the procedure provided by the manufacturer. CTNNB1 
Stealth Selected RNAiTM siRNAs were obtained from 
Life Technologies (HSS102460, HSS102461, referred 
as SiRNA1 and siRNA2 in  Figure 1,  respectively). 
The StealthTM RNAi negative control duplex (referred 
to as Scrambled) was used as a negative control for 
sequence-independent effects. Cells  were  collected 
72 h after transfection. For experiments described in 
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Figure 1. Oncogenic β-catenin drives LKB1 protein expression. (A) LKB1 accumulates in a large subset of CTNNB1-mutated HCCs. Western 
blotting analysis of LKB1, GLUL (a β-catenin target gene in the liver), and β-actin (loading control) in HCCs (T), selected based on their 
CTNNB1 mutational status. NT indicates matched nontumor liver tissue for each HCC sample. Two independent representative samples 
are shown. Quantification of the western blots for GLUL and LKB1 is shown on the right. Statistical significance was evaluated using a 
two-sample unpaired Student t-test between KO and WT. ***p < 0.001. **p < 0.01. *p < 0.05. n = 24 in each group. (B) Oncogenic β-catenin 
drives LKB1 protein expression in HuH6 and HepG2 cells. HuH6 and HepG2 cells were treated with scrambled siRNA (Sc) or various siRNAs 
against CTNNB1 mRNA (siRNA1, siRNA2) and harvested 72 h after transfection. Western blotting analysis of β-catenin, LKB1, and β-actin 
(loading control). The diagram above the western blots depicts the localization of the siRNAs along the β-catenin coding sequence and points 
to the position of siRNA2 in the deleted CTNNB1 sequence in HepG2 cells. (C) β-catenin drives LKB1 expression at the post-transcriptional 
level. RT-qPCR analysis of AXIN2 and LKB1 gene expression of HUH6 cells transfected with siRNA against CTNNB1 or scrambled siRNA, as 
described in (B). Mean from three independent experiments. Error bars: standard deviations. Statistical significance was evaluated using a 
two-sample unpaired Student’s t-test between KO and WT. ****p < 0.001. 
 
Figure 2, we used the SMARTpool technology of 
Dharmacon to inactivate CTNNB1 in CTNNB1-mutated 
(HUH6 and HepG2) and not mutated (HUH7) hepatoma 
cell lines. The siCTNNB1 (siCat) was ON-TARGET 
plus SMARTpool #L-003482-00-0005 and the scram- 
bled control (Sc) #D-001810-01-05. A total of 20 pmol 
siRNA was used per well in six-well plates. Cells were 
collected 48 h after transfection. 
 
RNA extraction and RT-PCR 
Total RNA was extracted from mouse tissues and cell 
lines with Trizol Reagent (Life Technologies) according 
to the manufacturer’s protocol. Reverse transcription 
was performed using 1 μg total RNA and the Tran- 
scriptor First Strand cDNA Synthesis Kit (Roche Diag- 
nostics, Life Technologies, Courtaboeuf, France) and 
random hexamers as primers. Quantitative PCR reac- 
tions were run using the Light Cycler 480 Sybr Green 
I Master Kit (Roche Diagnostics) and specific primers 
(Eurogentec, Eurogentec France SASU, Nantes, France) 
on a Light Cycler 480 thermocycler (Roche Diagnos- 
tics). Values were normalized to 18 S ribosomal RNA 
levels. For the mouse data, expression of the β-catenin 
target genes was expressed relative to that in the livers 
of WT animals (n = 6 animals) as an n-fold ratio. For the 
human data, gene expression in the tumor samples was 
compared to the mean level of the corresponding gene 
expression in normal liver tissues (n = 6), expressed as 
an n-fold ratio. For human hepatoma cell lines data, 
gene expression in the siRNA CTNNB1-treated samples 
was compared to the scrambled-treated samples (n = 3). 
The relative amount of RNA was calculated using the 
2-delta CT method. Primer sequences are shown in 
supplementary material, Table S1. 
 
Immunoblotting  analyses 
Total protein extracts from human and mouse  liver 
were obtained from 20 to 200 mg frozen tissue that 
was bead-mill homogenized in lysis  buffer  (50 mM 
Tris – HCl pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM 
DTT, 0.1 mM 4-benzenesulfonyl fluoride, and 1% 
Triton X-100), supplemented with a mixture of protease 
and phosphatase inhibitors (Roche Diagnostics) in a 
10 μl/μg ratio using a TissueLyser disruption system 
 = 
 
 
 
 
 
Figure 2. CTNNB1-mutated HCC express a hepatic Lkb1 program. (A) LKB1 expression profile in CTNNB1-mutated HCC. RT-qPCR was 
performed for the positively- (GLUL, SLC13A3, AQP9) and negatively- (SLPI, LSR, RCAN3, GSTP1, SGK1, ELOVL7) LKB1-regulated genes 
described in supplementary material, Figure S1 using mRNA isolated from normal human liver (N), CTNNB1-mutated HCC (M), and 
nonmutated HCC (NM). (B) LKB1 expression profile in human hepatoma cell line after β-catenin silencing. β-Catenin silencing was performed 
using siRNA against CTNNB1 (siCat) and scrambled (Sc) as controls. RT-qPCR was performed for CTNNB1 and the positive (SLC13A3) and 
negative (SLPI, RCAN3, ELOVL7, GSTP1) LKB1-related genes. HuH6 and HepG2 are CTNNB1-mutated hepatoma cell lines, while HuH7 is not 
mutated for CTNNB1. *p < 0.05; **p < 0.01; ***p < 0.001. 
 
(Qiagen, Hilder, Germany). Samples were centrifuged at 
13 000 × g for 10 min at 4 ∘C, and the supernatants were 
collected and stored at −80 ∘C until analysis. For human 
hepatoma cell lines, protein was extracted from the 
six-well plates using Laemmli buffer (Sigma-Aldrich, 
Saint-Quentin Fallavier, France). Proteins were resolved 
by SDS – PAGE and then transferred to nitrocellulose, 
which was then blocked using 5% BSA or 5% milk. 
Blots were incubated with specific primary antibodies 
overnight   at   4 ∘C,   washed,   incubated   with   the 
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corresponding horseradish peroxidase-conjugated 
secondary antibodies (Cell Signaling Technology, 
Ozyme, Saint-Quentin en Yvelines, France), and devel- 
oped by enhanced chemiluminescence (Thermo Fisher 
Scientific, Waltham, MA, USA). Images were recorded 
using a 3.2-megapixel super CCD camera driven by a 
LAS 4000 mini device (GE Healthcare Europe GmBH, 
Velizy Villacoublay, France) and quantified using 
Multigauge software from Fujifilm (Fujifilm France, 
Asnières, France). Expression was standardized to the 
β-actin level and normalized to a nontumor sample that 
was set to 1. Primary antibodies were purchased from 
Cell Signaling Technology [LKB1: clone D60C5, dilu- 
tion 1/1000; β-actin (8456, dilution 1/2000); GAPDH 
(97166, dilution 1/500); Gsk3β (4337, dilution 1/1000), 
phosphoGsk3β (9323 (S9), dilution 1/2000)] and BD 
Biosciences (BD, Transduction Laboratories, Rungis, 
France) (β-catenin (811054, dilution 1/2000) and 
glutamine synthase (GLUL) (610518, dilution 1/2000). 
 
Immunohistochemistry and in situ hybridization 
Mouse livers were cut into 3-mm-thick slices, fixed 
in 10% formalin for 12 h, and embedded in paraffin. 
For morphological analysis, sections were cut at 2-μm 
thickness, dewaxed, rehydrated, and stained with hema- 
toxylin and eosin. The protocols for glutamine syn- 
thetase immunohistochemistry and in situ hybridization 
have been described previously [6]. 
 
Human gene expression analysis 
The data for GSE62232, which includes Affymetrix 
U133plus v2 array (GPL570) data for 81 HCC liver 
tumors samples, were downloaded in an already nor- 
malized matrix format via Gene Expression Omnibus. 
The CTNNB1 mutations in this sample collection were 
reported in [22,23]. Hierarchical clustering was per- 
formed using Genesis clustering software as described 
in [24]. 
 
Statistical analysis 
Data were analyzed using unpaired t-tests with Welch’s 
correction in GraphPad Prism 7.04 (GraphPad Inc., San 
Diego, CA, USA). 
 
 
Results 
 
Activated LKB1 signaling occurs 
in CTNNB1-mutated HCC 
We first analyzed LKB1 protein expression in a series 
of 48 human HCCs, selected based on their CTNNB1 
mutational status (24  with  CTNNB1  mutations  and 
24 without). Total proteins were extracted from cry- 
oconserved tumor samples and matched nontumor 
liver samples for each patient. The very high expres- 
sion of GLUL, a well-known β-catenin target in the 
liver [25], confirmed activation of the β-catenin path- 
way in the CTNNB1-mutated tumors. LKB1 protein 
levels were significantly higher in CTNNB1-mutated 
HCCs than in nontumor liver tissue, whereas those in 
non-CTNNB1-mutated HCCs were no different from 
those in nontumor liver tissue (Figure 1A). 
We then investigated whether activated β-catenin was 
able to stimulate LKB1 protein expression in hepatoma 
cell lines. HuH6 and HepG2 are two hepatoma cell 
lines with gain-of-function mutation alterations of 
CTNNB1 (a p. G32V mutation and p. 25_140 deletion, 
respectively, within the DNA sequence encoding the 
degradation domain of β-catenin) [26]. In HuH6, two 
different siRNAs against CTNNB1 mRNA, but not a 
scrambled siRNA, decreased LKB1 protein expression 
in parallel with β-catenin inactivation (Figure 1B). This 
was also true for HepG2 cells with siRNA1, but not 
siRNA2, which is targeted against a sequence deleted 
in the HepG2 mutated allele, preventing its inacti- 
vation (Figure 1B). This result shows that activation 
of the mutant β-catenin was required for the control 
of LKB1 protein expression (Figure 1B). While, as 
expected, RT-qPCR analyses showed that the mRNA 
levels of the canonical β-catenin target gene AXIN2 
were strongly reduced after CTNNB1 inactivation 
mediated by siRNA, the  LKB1  mRNA  levels  were 
not affected by β-catenin silencing, indicating that the 
decrease in LKB1 protein observed in Figure 1B was 
not associated with a decrease in LKB1 mRNA level 
(Figure 1C). These results show that the aberrant activa- 
tion of β-catenin signaling induced the accumulation of 
LKB1 protein in liver tumor cells, which was regulated 
post-transcriptionally. 
We then explored whether CTNNB1-mutated HCC 
expressed an LKB1 program. This was performed using 
the liver Lkb1 signature of 253 genes that we recently 
obtained from the study of mice bearing a specific Lkb1 
deletion in embryonic liver hepatoblasts, Lkb1lox,lox; 
Alfp-Cre mice, designated LKB1KOLivemb [23]. We 
studied the human HCC public dataset (GSE62232, 
81 samples), for  which  data  on  the  genetic  status 
of CTNNB1 and the RNA expression profile were 
available (described in reference [24]). Unsupervised 
hierarchical clustering of the GSE62232 human HCC 
dataset, using the hepatic Lkb1 signature, grouped 
almost all CTNNB1-mutated HCCs within a single 
cluster, showing that most CTNNB1-mutated HCCs 
share a hepatic Lkb1 program (see supplementary 
material, Figure S1). The hepatic Lkb1 signature was 
composed of genes up- and downregulated  in  the 
liver of KO versus WT animals and accounted for a 
program suppressed by Lkb1 in mouse hepatocytes. 
Thus, most (19/27) CTNNB1-mutated HCCs displayed 
activated LKB1 signaling (see supplementary  mate- 
rial, Figure S1). We confirmed these results using an 
independent cohort of human HCCs, consisting of 
CTNNB1-mutated and non-CTNNB1-mutated tumors, 
by RT-qPCR. The expression of several LKB1-related 
genes was statistically enhanced (GLUL, SLC13A3, 
AQP9)  or  repressed  (SLPI,  LSR,  RCAN3,  GSTP1, 
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SGK1, ELOVL7) in CTNNB1-mutated HCCs relative 
to nonmutated HCCs (Figure 2A). We validated the 
cross talk between β-catenin and LKB1 by analyzing 
the LKB1 gene expression profile in CTNNB1-mutated 
(HuH6, HepG2)  and  nonmutated  (HuH7)  HCC  cell 
lines after β-catenin silencing using siRNA. Although 
some genes were discarded as they were not expressed 
in the hepatoma cell lines, the expression of the positive 
and negative LKB1-related genes were significantly 
repressed or enhanced, respectively, after β-catenin 
silencing in CTNNB1-mutated HCC cell lines but 
were not affected in the nonmutated HCC cell line 
(Figure 2B). 
Overall, our data show that β-catenin signaling in 
CTNNB1-mutated HCCs induces a post-transcriptional 
accumulation of LKB1, which in turn activates an LKB1 
program likely contributing to the specific histological 
appearance of CTNNB1-mutated HCCs. 
 
LKB1 positively regulates β-catenin signaling 
in liver zonation 
Cross talk between Wnt/β-catenin and LKB1 signal- 
ing has been described in several studies, with often 
conflicting results [15 – 22]. The first pioneering study 
showed LKB1 to be upstream of β-catenin signaling 
and to be required for full activation of β-catenin 
signaling in Xenopus development [15]. We explored 
whether LKB1 may control  Wnt/β-catenin  signal- 
ing in the mouse liver in a physiological situation in 
which the canonical Wnt pathway is known to have a 
critical function, such as metabolic zonation [6]. We 
thus examined liver zonation in Lkb1-deficient mice 
(LKB1KOLivemb) [23]. Immunohistochemistry and in 
situ hybridization for Glul (glutamine synthase) and 
Arg1 (arginase 1), together with immunohistochemistry 
for Lect2 (Leukocyte cell-derived chemotaxin 2) and 
Hal (histidine ammonia-lyase), showed that Lkb1 dele- 
tion strongly affected liver zonation in LKB1KOLivemb 
mice, with almost complete loss of the perivenous 
expression of Glul and Lect2, while the periportally 
expressed gene Arg1 and Hal protein were overex- 
pressed (Figure 3A). Accordingly, analysis of a 16-gene 
signature of liver β-catenin target genes confirmed 
decreased Wnt/β-catenin signaling in LKB1KOLivemb 
mice relative to controls. This decrease in β-catenin 
activity was confirmed by RT-qPCR using a different 
group of animals (Figure 3B,C). These results show that 
Lkb1 is a positive modulator of Wnt/β-catenin signaling 
during liver development and is required for the full 
establishment of liver zonation. 
Previous studies also reported that LKB1 controls the 
Wnt/β-catenin pathway through two different kinases, 
GSK3β and PAR1A (MARK3) [15 – 17]. We analyzed 
the phosphorylation status of GSK3β (pS9-GSK3β) in 
the livers of LKB1KOLivemb mice by western blotting 
and observed higher levels of pS9-GSK3β in the mutant 
mice than in controls (Figure 3D). We were unable 
to detect phosphorylation of Par1a (Mark3) or  any 
other Mark (data not shown). The decrease in β-catenin 
signaling activity in LKBKOLivemb mice did not corre- 
late with increased phosphorylation of GSK3β on S9 
(known to inhibit GSK3β function), normally associated 
with increased β-catenin activity. These results suggest 
that Lkb1 controls the canonical Wnt pathway in hepa- 
tocytes, independent of GSK3β. 
 
 
Discussion 
 
Wnt/β-catenin signaling  regulates  critical  functions 
in liver physiology, and its aberrant activation is 
found  in  several  liver  diseases,  including  HCC 
[27]. HCCs generally display a high level of het- 
erogeneity [28]. However, we previously showed that 
CTNNB1-mutated HCCs form a homogeneous group 
of tumors, with specific cell metabolism, polarity, and 
growth hallmarks [4]. Here, we investigated whether 
the activation of LKB1 signaling could explain the 
specific phenotype of CTNNB1-mutated HCC as LKB1 
is considered to be a master regulator of cell growth, 
metabolism, survival, and polarity [7,8]. We showed that 
CTNNB1-mutated HCCs display significantly higher 
LKB1 protein expression than non-CTNNB1-mutated 
HCCs. CTNNB1-mutated HCCs expressed a hepatic 
LKB1 signature that we recently identified in mouse 
Lkb1-deficient livers [23]. Reciprocal positive control 
of the canonical Wnt pathway by Lkb1 during devel- 
opment was previously described [15]. This led us to 
investigate whether Lkb1 controls liver metabolic zona- 
tion, a well-established function of β-catenin signaling 
in the liver [6]. Our data show that Lkb1 is required for 
the full activation of β-catenin signaling in mouse liver 
and is thus a positive regulator of the establishment of 
metabolic zonation. 
Cross talk between Wnt/β-catenin and LKB1 signal- 
ing in both directions (β-catenin toward LKB1 and LKB1 
toward β-catenin) has been described in many studies. 
It appears that the dialog depends on the context, 
developmental or oncogenic, with either a positive or a 
negative impact [15 – 22]. The molecular mechanisms 
involved are yet to be determined for all contexts. Here, 
we showed that oncogenic β-catenin signaling induced 
the accumulation of LKB1 protein in CTNNB1-mutated 
HCC. The regulation of LKB1 is complex and still 
not well characterized. It is controlled epigenetically, 
transcriptionally, and post-translationally through the 
modulation of protein stability [29]. Little is known 
concerning the mechanisms that regulate the stability 
of LKB1 protein: the ubiquitin ligase CHIP has been 
proposed to be involved [30], but this still needs to be 
confirmed. A recent study reported overexpression of 
LKB1 in human HCC that predicts poor survival out- 
comes. However, this was at the mRNA level and, thus, 
does not coincide with our study in which we showed 
accumulation of the LKB1 protein in CTNNB1-mutated 
HCC [31]. For the inverse relationship (control of β-
catenin signaling by Lkb1), we showed that deletion of 
Lkb1 in mouse hepatocytes led to a marked decrease 
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Figure 3. Lkb1 positively regulates the Wnt canonical pathway and controls liver zonation. (A) Representative images for the expression of 
positively regulated β-catenin target genes, Glul, by immunohistochemistry and in situ hybridization and Lect2 by immunohistochemistry 
together with negatively regulated β-catenin target genes, Arg1, by in situ hybridization and Hal by immunohistochemistry. LKB1KOlivemb 
mutant and control and mice were 3 weeks old. (B) Heat map of the liver β-catenin target gene signature from the gene expression profile 
of LKBKOLivemb mice [23]. (C) RT-qPCR analysis of various positively (Axin2, Sp5, Glul, Lect2, Cyp2e1, Nkd1) regulated β-catenin target 
genes in 14-day-old control and LKBKOlivemb  mutant mice. n = 4 – 6 per group. Error bars: SEM. Statistical significance was evaluated using 
a two-sample unpaired Student’s t-test between KO and WT. *p < 0.05, **p < 0.01, ***p < 0.001. (D) Western blotting analysis showing 
increased pS9Gsk3β phosphorylation in mutant LKBKOLivemb mice relative to controls. 
 
in liver zonation controlled by Wnt/β-catenin. This was 
associated with increased phosphorylation of Gsk3β 
(S9-Gsk3β), leading to its inactivation. This result does 
not correlate with the decreased activation of β-catenin 
signaling we observed in the mutant mice and suggests 
that Lkb1 controls β-catenin signaling independent of 
Gsk3β. Overall, we identified positive reciprocal cross 
talk between β-catenin and LKB1, in which β-catenin 
activity induces LKB1 expression, leading to the acti- 
vation of LKB1 signaling, which in turn positively 
regulates β-catenin signaling. Such cross talk likely 
results in the amplification of β-catenin signaling by 
LKB1 in CTNNB1-mutated HCC. 
A positive role for LKB1 signaling in CTNNB1-
mutated HCC could suggest a synthetic lethal 
interaction between the Wnt pathway and LKB1. 
Although we have not been able to substantiate such an 
interaction (data not shown), a prosurvival role of LKB1 
has already been described. Indeed, Lkb1-deficient 
mouse embryonic fibroblasts showed resistance to 
transformation by oncogenes, suggesting that the high 
energetic demands of malignant transformation may 
be incompatible with Lkb1 loss [32]. Indeed, tumor 
cells must sense changes in their microenvironment to 
support unfettered cell proliferation, and the inability 
to respond to such environmental cues may lead to 
energetic stress and  ultimately  cell  death.  LKB1  is 
an energetic sensor, and its function is required for the 
survival of tumor cells under energy stress [13]. Accord- 
ingly, LKB1 is upregulated in human skin cancer cells 
and has been shown to be required for preventing apop- 
tosis in several human cancer cell lines overexpressing 
AKT [33]. Indeed, the prosurvival role of Lkb1 is not 
restricted to tumor cells but has also been described for 
quiescent hematopoietic stem cells [34 – 36]. Overall, 
these data show that LKB1 may provide cancer cells with 
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the metabolic flexibility required to survive under condi- 
tions of nutrient stress, thus conferring a growth advan- 
tage. LKB1 is likely to play this role in CTNNB1-mutated 
HCC. Furthermore, we recently showed that, in 
CTNNB1-mutated HCC, the tumor cells use fatty 
acids for energy, corroborating the lack of steatosis of 
those tumors [37]. This correlates with the positive role 
of LKB1 on fatty acid oxidation in the liver [7]. 
In addition to the function of LKB1 in metabolism, 
LKB1 signaling also controls cell polarity, inducing 
apicobasal polarity in a cell-autonomous manner [12]. 
This could partially explain the cholestatic phenotype of 
some CTNNB1-mutated HCCs, mainly those with pseu- 
doglandular structures [4]. The polarity present in acinar 
structures differs from the hepatic polarity required for 
the removal of bile excreted by hepatic cells [5]. It is 
possible that, in CTNNB1-mutated HCC, bile is secreted 
at the apical pole of tumor cells and accumulates in 
the lumen of acinar structures and cannot be removed 
from the tumor, leading to cholestasis. LKB1 has been 
reported to be involved in the establishment of liver cell 
polarity [23,38]. However, the cholestasis observed in 
CTNNB1-mutated HCC is also linked to the positive 
effect of β-catenin signaling on bile acid metabolism that 
we previously described [39]. 
In CTNNB1-mutated HCC, LKB1 may act as a 
tumor-suppressor gene, conferring a better prognosis, 
apicobasal polarity, and a well-differentiated growth 
pattern, but may also be required for tumor cell survival, 
acting more likely as an oncogene. Increased genomic 
instability is one of the various mechanisms by which 
LKB1 loss leads to tumor development [40]. Accord- 
ingly, we recently showed that Lkb1 inhibits liver cell 
proliferation and favors mitotic integrity [41] that could 
explain why CTNNB1-mutated HCCs  belong to the 
chromosomally stable HCC subclass [28]. 
We have demonstrated reciprocal cross talk between 
LKB1 and β-catenin, in which β-catenin enhances LKB1 
protein expression, favoring expression of the hepatic 
Lkb1 program that enhances β-catenin signaling. In 
the context of CTNNB1-mutated HCCs, such cross talk 
results in a positive activation loop that amplifies the 
β-catenin signaling. 
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